1. Home
  2. NMRA vs GSRT Comparison

NMRA vs GSRT Comparison

Compare NMRA & GSRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NMRA
  • GSRT
  • Stock Information
  • Founded
  • NMRA 2019
  • GSRT 2023
  • Country
  • NMRA United States
  • GSRT United States
  • Employees
  • NMRA N/A
  • GSRT N/A
  • Industry
  • NMRA
  • GSRT
  • Sector
  • NMRA
  • GSRT
  • Exchange
  • NMRA Nasdaq
  • GSRT Nasdaq
  • Market Cap
  • NMRA 287.6M
  • GSRT 292.6M
  • IPO Year
  • NMRA 2023
  • GSRT 2024
  • Fundamental
  • Price
  • NMRA $1.16
  • GSRT $10.01
  • Analyst Decision
  • NMRA Buy
  • GSRT
  • Analyst Count
  • NMRA 8
  • GSRT 0
  • Target Price
  • NMRA $10.14
  • GSRT N/A
  • AVG Volume (30 Days)
  • NMRA 1.3M
  • GSRT 3.7K
  • Earning Date
  • NMRA 03-03-2025
  • GSRT 01-01-0001
  • Dividend Yield
  • NMRA N/A
  • GSRT N/A
  • EPS Growth
  • NMRA N/A
  • GSRT N/A
  • EPS
  • NMRA N/A
  • GSRT N/A
  • Revenue
  • NMRA N/A
  • GSRT N/A
  • Revenue This Year
  • NMRA N/A
  • GSRT N/A
  • Revenue Next Year
  • NMRA N/A
  • GSRT N/A
  • P/E Ratio
  • NMRA N/A
  • GSRT N/A
  • Revenue Growth
  • NMRA N/A
  • GSRT N/A
  • 52 Week Low
  • NMRA $1.13
  • GSRT $9.97
  • 52 Week High
  • NMRA $17.19
  • GSRT $10.23
  • Technical
  • Relative Strength Index (RSI)
  • NMRA 28.13
  • GSRT N/A
  • Support Level
  • NMRA $1.13
  • GSRT N/A
  • Resistance Level
  • NMRA $1.48
  • GSRT N/A
  • Average True Range (ATR)
  • NMRA 0.13
  • GSRT 0.00
  • MACD
  • NMRA 0.06
  • GSRT 0.00
  • Stochastic Oscillator
  • NMRA 17.03
  • GSRT 0.00

About NMRA Neumora Therapeutics Inc.

Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has rapidly scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company expects to continue to progress in the development of its pipeline with the planned initiation of multiple clinical trials across its programs over the next 12 to 18 months, which supports numerous anticipated data readouts.

About GSRT GSR III Acquisition Corp. Ordinary Shares

GSR III Acquisition Corp is a blank check company.

Share on Social Networks: